A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Lake, Jordan E ^a   Tseng, Chi Hong ^a   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ABDOMINAL OBESITY; ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; MALE; OPEN STUDY; PILOT STUDY; SEX DIFFERENCE; SUBCUTANEOUS FAT; TREATMENT DURATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT CHANGE;

ADIPOSITY; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZIMIDAZOLES; BENZOATES; FEMALE; GLUCOSE; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MALE; MIDDLE AGED; ORGAN SIZE; PILOT PROJECTS; SEX FACTORS;

EID: 84875039474     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058135     Document Type: Article

References (44)

1. Hadigan C, Meigs JB, Wilson PW, D'Agostino RB, Davis B, et al. (2003) Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 36: 909-916.
2. Currier J, Scherzer R, Bacchetti P, Heymsfield S, Lee D, et al. (2008) Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 48: 35-43.
3. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, et al. (2008) The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 48: 44-52.
4. Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, et al. (2011) Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care 23: 929-938.
5. Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, et al. (2005) Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 39: 44-54.
6. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, et al. (2000) Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284: 472-477.
7. Kohli R, Shevitz A, Gorbach S, Wanke C, (2007) A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 8: 420-426.
8. Caron M, Vigouroux C, Bastard JP, Capeau J, (2009) Antiretroviral-Related Adipocyte Dysfunction and Lipodystrophy in HIV-Infected Patients: Alteration of the PPARgamma-Dependent Pathways. PPAR Res 2009: 507141.
9. Lemoine M, Capeau J, Serfaty L, (2009) PPAR and Liver Injury in HIV-Infected Patients. PPAR Res 2009: 906167.
10. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, et al. (2002) Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163-170.
11. Lo J, You SM, Canavan B, Liebau J, Beltrani G, et al. (2008) Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300: 509-519.
12. Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, et al. (2008) Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 9: 254-268.
13. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, et al. (2008) Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22: 1719-1728.
14. Falutz J, Allas S, Blot K, Potvin D, Kotler D, et al. (2007) Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357: 2359-2370.
15. Shimabukuro M, Tanaka H, Shimabukuro T, (2007) Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25: 841-848.
16. Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, et al. (2007) Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 32: 261-268.
17. Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, et al. (2007) Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 30: 1205-1210.
18. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, et al. (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertens 47: 1003-1009.
19. Mori Y, Itoh Y, Tajima N, (2007) Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 20: 431-436.
20. Sharma AM, (2006) The obese patient with diabetes mellitus: from research targets to treatment options. Am J Med 119: S17-23.
21. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, et al. (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784-2791.
22. Ohashi K, Ouchi N, Matsuzawa Y, (2011) Adiponectin and hypertension. Am J Hypertens 24: 263-269.
23. Nakagami H, Morishita R, (2011) Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-gamma. Curr Vasc Pharmacol 9: 162-166.
24. Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J, (2012) Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Eur Rev Med Pharmacol Sci 16: 491-498.
25. Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, et al. (2011) Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther 16: 639-645.
26. Makino H, Haneda M, Babazono T, Moriya T, Ito S, et al. (2008) Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 31: 657-664.
27. Shuster A, Patlas M, Pinthus JH, Mourtzakis M, (2012) The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol 85: 1-10.
28. Falutz JAH, Marsolais C, Morin J, Mamputu JC, Soulban G, Grinspoon S, (2011) Metabolic Risk Factors in Responders to Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Excess Abdominal Fat. Antivir Ther 16: A29.
29. Kubik M, Chudek J, Adamczak M, Wiecek A, (2012) Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension. Kidney Blood Press Res 35: 281-289.
30. Huang GZ, Tang YH, Wang BY, Zhang B, Hu TJ, et al. (2011) Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J 32: 1017-1021.
31. Boccara F, Auclair M, Cohen A, Lefevre C, Prot M, et al. (2010) HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther 15: 363-375.
32. Meade TW, Imeson JD, Gordon D, Peart WS, (1983) The epidemiology of plasma renin. Clin Sci (Lond) 64: 273-280.
33. Chappell MC, (2010) Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation. Arthritis Res Ther 12: 128.
34. Walther T, Stepan H, (2007) Agonist autoantibodies against the angiotensin AT1 receptor in renal and hypertensive disorders. Curr Hypertens Rep 9: 128-132.
35. Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, et al. (2011) Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart 97: 479-484.
36. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
37. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, et al. (2010) Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 55: 316-322.
38. Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H, (2003) C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 32: 210-214.
39. Fichtenbaum CJ, (2011) Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep 13: 94-101.
40. Barbaro G, (2007) Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des 13: 2208-2213.
41. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S, (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56: 1010-1013.
42. Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G, (2007) Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 13: 2169-2175.
43. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H, (2003) Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS 17: 521-530.
44. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, et al. (2010) Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 7: e1000384.